BioWorld

Jan. 4, 2007

View Archived Issues

Cytokinetics Forms $725M Heart Disease Alliance With Amgen

Providing leverage for a small-molecule program targeted at heart failure, Cytokinetics Inc. is collaborating with Amgen Inc. in a deal potentially worth $725 million. (BioWorld Today) Read More

Genentech Paying Exelixis $40M In MEK Inhibitor Deal

Read More

Cloned Cows Safe, Knockouts Healthy, But Not In Supermarket

Read More

FivePrime Signs Discovery Deal With Centocor; $15M Up Front

Read More

VaxGen Future Unclear With Additional $51M Celltrion Sale

Read More

FDA Signs Off On Poniard's Phase III Picoplatin Protocol

Read More

Other News To Note

Read More

Clinic Roundup

Read More